GI CANCERS

Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.

Zolbetuximab could become the first CLDN18.2-targeted therapy approved for this patient population in the US.

VCN-01, an adenovirus therapy, received fast track designation from the FDA for treating metastatic pancreatic cancer in combination with standard chemotherapy.

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.

Using neoadjuvant atezolizumab followed by atezolizumab plus chemotherapy before surgery for gastric or gastroesophageal junction tumors appeared to be effective and warrants further study.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

A biologics license application for zanidatamab is being reviewed by the FDA for treating previously treated, HER2-positive biliary tract cancer.

During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.

Daniel H. Ahn, DO, discusses how regorafenib continues to benefit patients with advanced colorectal cancer as researchers look to modify treatment strategies with the therapy.

A fast track designation from the FDA has been given to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.

Cambritaxestat, a first-in-class therapy in development for highly fibrotic cancer indications that overexpress autotaxin, has been granted an orphan drug designation from the FDA in pancreatic cancer.

In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.

The FDA has accepted the biologics license application of tislelizumab in combination with chemotherapy for the treatment of locally advanced or metastatic gastric or gastroesophageal cancers.

The FDA has granted an investigational new drug application to the investigational chimeric antigen receptor T-cell therapy IMC001 for the treatment of EpCAM-positive advanced gastrointestinal tumors.

IMM-1-104 has gained a fast track designation from the FDA for the treatment of patients with pancreatic ductal adenocarcinoma who have progressed after 1 line of treatment.

A phase 2 trial for the treatment of gastric, esophageal, and gastroesophageal junction cancer is evaluating agenT-797 with botensilimab, balstilimab, ramucirumab, and paclitaxel.